Sable Bio
AI NativeEmpowering Discovery: Precision Insights for Safer Drug Targets.
Est 2023
Empowering Discovery: Precision Insights for Safer Drug Targets.
Published Oct 7, 2026
The vendor reported increasing adoption through commercial agreements in its public materials; independent market share or adoption metrics were not identified in this research pass.
| Starting Price | Not publicly listed (demo-led sales) | Not publicly listed (demo-led sales) | Academic access available; commercial license required; offers trial options (no public price) |
| Primary Use Case | Target-centric safety assessment workflows; early target decisions; due diligence | Broader in silico toxicology modeling and regulatory reporting (compound-focused) | Target safety and efficacy exploration with text/data mining; academic access plus commercial licensing |
| Key Strength | Integrates multiple evidence types with interactive reporting tailored to target-level assessments | Breadth of toxicology modeling approaches and regulatory-focused outputs | Backing from TNO; platform plus TSA services; academic accessibility |
| Key Weakness | Limited independent validation materials and third-party reviews; pricing and methodology transparency need verification | May be oriented toward compound-level modeling rather than target-level TSA narratives | Commercial licensing terms may be unclear publicly and interpretation effort may be required |
—